🔗 Share this article

Ministers and senior MPs have expressed alarm that the United Kingdom's series of deals with the US administration are "built on sand." This comes after revelations that a much-touted deal on medicines, which promises zero tariffs in exchange for the NHS paying more, lacks any detailed agreement beyond broad headline terms contained within government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, promoted as a "landmark" achievement, is still an "agreement in principle" without a signed legal text. It has been highlighted that the press releases from the UK and US governments describe the deal in divergent terms. The British version emphasizes securing "duty-free access" as a singular success, while the American announcement highlights the expectation for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has promised concessions to increase medicine costs in return for little more than a assurance from President Trump," stated David Henig, a trade expert. "We know he has a record of not following through on agreements."

Broader Instability and a Paused Tech Deal

Anxieties have been intensified by Washington's move to suspend the major technology agreement, which was previously described as "a huge leap forward" in the bilateral relationship. The US cited a lack of progress from the UK on lowering trade barriers as the reason for the pause.

In a separate development, concessions secured for British farmers as part of an earlier tariff deal have not been formally signed off by the US, despite a looming January deadline. "It is our belief that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have admitted unease that the government's agreements with the US are unstable and unpredictable. One minister reportedly said the series of agreements as "built on sand," while another framed the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, remarked: "Perhaps most shocking than Trump's temper tantrums is the UK government's naive belief that his administration is a reliable partner. The NHS is too precious to be gambled with."

Official Reassurances and Concrete Outcomes

Officials have sought to reduce the risk of the US backing out of the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been pushing for the agreement, wanting clarity on imports and pricing, making it more concrete than the paused tech deal.

Officials admit that unpredictability is a feature of dealing with the Trump administration. However, they maintain that the UK has achieved real benefits for businesses, such as preferential tariff rates compared to other nations. "Our achievement of 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a solid gain," one official said.

However, problems have emerged in implementing the initial US-UK accord. Promised access for British beef have not materialized, and the pledge to "eliminate duties on UK metals" has is still pending, with tariffs remaining at 25%.

Looking ahead, the two sides have agreed to resume talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.